The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.
Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.
To get a better understanding of the situation and how the future months could unfold, MPR sat down with Joshua Barocas, MD, an Assistant Professor of Medicine at the Boston University School of Medicine and Infectious Diseases physician at Boston Medical Center.
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Primary effectiveness of no additional surgical or interventional procedures related to the device and acceptable heart blood flow function at 6 months, was achieved by 89.2%.
Ponesimod is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
Patients were randomized to receive either ruxolitinib 5mg twice daily (BID) plus standard of care (SoC), ruxolitinib 15mg BID plus SoC or placebo plus SoC.
This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; Approval in acute bacterial skin and skin structure infections; And results from the tocilizumab-remdesivir combo trial.
Foscarnet sodium injection is indicated to treat cytomegalovirus retinitis in patients with AIDS and acyclovir-resistant mucocutaneous HSV in immunocompromised patients.
This week it’s all COVID related news; There’s new CDC guidance for those who are vaccinated; A first over-the-counter test that doesn’t require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there’s reports of vaccine local reactions.
